Completed Clinical Trials

S.No.  IndicationPhase  Year   Study  Duration  No. Pt.
 Screened		  No. of Pt.  Randomized  Rating Scales
  Used
 1Bipolar-1-disorderIII2005-0852 Weeks  120118
YMRS, PANSS, SAS, BARS, AIMS, HAM-D, CGI-I, CGI-S


  2DepressionIV2005-0726 Weeks          70 
HAMD-17, MADRS, CGI-I, CGI-S, CGI-I, CGI-S


  3SchizophreniaIV2005-0852 Weeks          80 Safety Outcome Study


  4SchizophreniaIII2006-0726 Weeks  17  15
ESRS, PANSS, CGI-I, CGI-S, SDS, M.I.N.I, RDQ


  5Major Depressive DisorderII2007-0810 Weeks   15   14HAMD-17,MADRS,CGI-I,CGI-S,M.I.N.I,RDQ


  6Schizophrenia in adolescentsII2007-0826 Weeks   5   3PANSS,BARS,AIMS,SAS


  7Acute ManiaIII2007-086 Weeks  18  15
YMRS,MADRS,CGI-I,CGI-S,HAMD-17,SAS,BARS,AIMS


8Major Depressive DisorderII2007-086 Weeks2015
HAMD-17, HAMD-21, MPS, CGI-I, QIDS-SR, SF-36, BSI, HAMA, OAS-M, ASEX, ISI, FSS, M.I.N.I, YMRS


9SchizoaffectiveIII2007-086 Weeks1412
PANSS, CGI-S-SA,ISST,SUMD, AIMS, SAS, HAMD-21, YMRS


10SchizoaffectiveIII2007-086 Weeks98
PANSS, CGI-S-SA,ISST,SUMD, AIMS, SAS, HAMD-21, YMRS


11Acute ManiaII2008-086 Weeks2316
SCID, PANSS, CGI-S, CGI-I,  AIMS, SAS, MADRS, BARS


12SchizophreniaIV2006104 Weeks2020
ESRS, PANSS,CGI, PSP, SF-36, ISST, SUMD, Cognitive Battery


13Alzheimer’s DiseaseIII200726 Weeks1512
MMSE, CES-D,CSDD, SIB,CIBIS,CIBIC,ADCS ADL, QoL AD, EQ 5D,SCB,TES,TOS,GATs,


14SchizophreniaIIb20086 Weeks3938PANSS,CDSS,CGI-S,CGI-I, ESRS, RDQ, MODIFIED ISST, M.I.N.I PLUS,MSQ, LOF, BACs.


15SchizophreniaIIb20086 Weeks  2925 SCID, SCI-PANSS, CGI-S, CGI-I, NSA 16, BARS, SAS, AIMS


16Major Depressive DisorderII200818 Weeks  2511*HAMD 17, QIDS, CGI-S, CGI-I, MADRA,SDS, STS, SIS, M.I.N.I


17Alzheimer’s DiseaseIV200852 Weeks      4 MMSE, SIB, CIBIS, CIBIC, ADCS ADL, QoL-AD, EQ 5D, SCB, TES, TOS, GATs,


18SchizophreniaIIb20096 Weeks    19 PANSS, CDSS, CGI-S, CGI-I, ESRS, RDQ, MODIFIED ISST, MSQ, LOF,BACs.


19SchizophreniaIII200952 Weeks  103**PANSS, CDSS, CGI-S, CGI-I, S-QoL, DAI, GAF, PSP, CSRI, AIMS, BARS, SAS


 

   

* Study was to asses efficacy of augmenting agent with SSRI. Only partial responders in open label phase were randomized into double blind phase of study. The responder groups and non-responder groups were not eligible for randomization.

** Study was terminated by sponsors at all sites soon after initiation.